3q27 (BCL6), 8q24 (MYC), and 14q32 (IGH), suggesting a complex karyotype. Further workup including MRI, positron emission tomographic (PET) scan, and bone marrow biopsy did not reveal any local or distant metastatic disease with final staging of stage 1 PBL with high-risk features. The patient elected to undergo 6 cycles of chemotherapy to include infusion with etoposide, vincristine, doxorubicin with bolus of cyclophosphamide, and prednisone with the addition of rituximab. After 1 round of therapy the patient developed neutropenic fevers so he was switched to cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab, which was well tolerated allowing for completion of chemotherapy. Posttreatment PET scan did not reveal any recurrent or active lymphoma, lymphadenopathy, or splenomegaly.Discussion | Plasmablastic lymphoma is a rare aggressive large B-cell neoplasm, often associated with EBV infection. 1 Originally described in 1997 in acquired immunodeficiency syndrome patients, 2 PBL has also been described in immunosuppressed, posttransplant, and immunocompetent patients. 4 A recent review 3 identified 590 patients with PBL with a wide age range of effected individuals, with most individuals being adult males. Though the pathogenesis of PBL is incompletely understood, the cell of origin is theorized to be blastic proliferating B cells that have activated plasma cell gene expression programs. 1 Both EBV infection and MYC oncogene dysregulation have been thought to contribute to the development of PBL where EBV infection has been shown to inhibit B-cell apoptosis and MYC translocation has been shown to impair the response to DNA damage through the loss of p53. 3 MYC rearrangement, as seen in approximately 50% of cases, is associated with decreased overall survival in HIV-positive patients with PBL. 4 Survival for patients with PBL is low with the median survival being 3 and 4 months for HIV-positive and HIV-negative patients, respectively. 5 Treatment is typically chemotherapy using cyclophosphamide, doxorubicin, vincristine, and prednisone with some studies reporting the use of etoposide. As was the case for this patient, recent studies have demonstrated possible improved complete response rates in patients receiving rituximab, although the mechanism remains unclear. 6 Though PBL presents in the head and neck, most cases are identified in the oral cavity and gastrointestinal tract. [2][3][4] Although reports exist of sinonasal PBL, to our knowledge this represents the first report of PBL originating from the nasal septum.